Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163640 · ClinicalTrials.gov registry record · NA
Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response
A NA study, sponsored by Reproductive Medicine Associates of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT04163640: Completed NA study, sponsored by Reproductive Medicine Associates of New Jersey.
NCT04163640 is a NA study that has completed, run by Reproductive Medicine Associates of New Jersey. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04163640, a NA study, has completed, sponsored by Reproductive Medicine Associates of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The objective of this study is to perform a prospective randomized controlled trial seeking to characterize the effects of intra-ovarian injection of platelet rich plasma (PRP) on biomarkers of ovarian reserve as well as IVF outcomes in women with primary ovarian insufficiency (POI) and poor ovarian response (POR) who decline the use of an egg donor to establish a pregnancy.
Primary Outcome
success or failure is determined by the retrieval of at least one mature oocyte
Interventions
- OTHER intra-ovarian platelet rich plasma injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2023-07-21 |
| Phase | NA |
What the finished NCT04163640 record still lists
NCT04163640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which intra-ovarian platelet rich plasma injection is the first listed.
NCT04163640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04163640 about?
NCT04163640 is a clinical study titled "Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response". The objective of this study is to perform a prospective randomized controlled trial seeking to characterize the effects of intra-ovarian injection of platelet rich plasma (PRP) on biomarkers of ovarian reserve as well as IVF outcomes in women with primary ovarian insufficiency (POI) and poor ovarian...
What is the current status of trial NCT04163640?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2020-02-24. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT04163640?
The interventions under investigation include: intra-ovarian platelet rich plasma injection (OTHER).
Who is sponsoring clinical trial NCT04163640?
This trial is sponsored by Reproductive Medicine Associates of New Jersey, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04163640's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI